👉SER is TODAY’S #1 ALERT 👈

Hey Folks, Jeff Bishop here,

My flurry of double-digit “tactical trade” idea winners continued yesterday with an encrypted messaging/social-media stock that ripped as high as 26%:

Right now, I’m eyeing a clinical-stage biotech stock that has ramped up 15.5% YTD.

And when I alerted this one in December, it rocketed as high as 26% the same day. 🚀

💥Go ahead and pull up Serina Therapeutics (SER) on your favorite platform 💥

You’ll see that the stock’s ascent began in earnest in mid-March, and that it recovered swiftly from the market’s early-April downturn.

It has picked up solid steam over the past three weeks (it’s up 17.5% since its May 21 low), and I’m looking at this one as a pure momentum play today.

👉  SER is TODAY’S #1 ALERT 👈

As always, you’ll want to do your own research on the company, but here are the five things I think are most important:

1. Origin Story in a Non‑traditional Biotech Hub 🧪

SER isn’t your typical Boston or San Francisco biotech. It’s located in Huntsville, Alabama, at the HudsonAlpha Institute of Biotechnology. 

True to its roots, it didn’t start with elite VC backers. It was self-financed by the founders and local investors after their prior venture sold off. 

That scrappy, homegrown DNA gives it a unique pedigree and culture, fueling its next-gen polymer drug tech.

2. POZ Platform™ — A PEG-killer? 😎

At their prior venture, SER co-founders Dr. Milton Harris and Dr. Michael Bentley developed the first-generation of “PEGylated” drugs. 

PEG tech “became the standard for delivery of protein drugs and has enabled 30 FDA approved products that have since generated over $140B in cumulative sales.” [emphasis added]

SER was founded to address the limitations of PEG by developing a proprietary polymer system called POZ, “enabling new treatment paradigms for patients suffering from some of the world’s most challenging diseases.”

It’s designed for once-weekly, controlled-release dosing via injections — covering small molecules, RNA, antibody-drug conjugates, and more. 

It’s a modular delivery platform that lets SER plug and play payloads across indications.

3. Headlining SER‑252 for Parkinson’s 🎯

SER’s lead asset, SER‑252 (POZ-apomorphine), is designed to deliver continuous dopaminergic stimulation in advanced Parkinson’s. 

The company has secured “$15 million in equity financing since late 2024, including a $10 million two-tranche investment from JuvVentures (closed in January 2025) and a $5 million private placement in April 2025 from a Securities Purchase Agreement entered with certain board directors and investors.”

The funding will help SER advance SER-252 to a Phase 1b clinical trial in Q4 2025.

In May 2024, SER partnered with Enable Injections to use its wearable enFuse™ device for subcutaneous, controlled delivery, allowing patients to self-administer SER-252 from the comfort of their homes. 

(Previous apomorphine treatments required “daily and time-consuming infusions through an electronic pump that not only burdens patients and providers, but can cause significant skin reactions.”)

4. Lean balance sheet, high-stakes runway 💸

Financially speaking, SER had about $4.3 million in cash as of March 31 plus the $5M pull from April 2025 funding — giving them a runway through Q3 2025. 

That’s tight, but SER has also offloaded its UniverXome subsidiary in January 2025 to erase $11.2 million in debt, cleaning the slate heading into its clinical stage. 

The company is counting on hitting clinical milestones to unlock additional capital.

5. Diversified Platform & Strategic Collaborations 🤝

Beyond Parkinson’s, SER is actively working to license or partner its POZ tech across multiple therapeutic areas — RNA vaccines/lipid nanoparticle delivery (including potential mRNA COVID-style vaccines), antibody-drug conjugates in oncology, and small-molecule delivery improvements. 

SER isn’t a one-trick pony — it’s a platform play.

Final Thoughts

On May 9, JonesTrading reiterated a 12-month price target of $11 for SER — 86% upside from yesterday’s closing price.

For a deeper dive into the science behind the POZ Platform and its possible indications, check out this April 2025 investor presentation and the company website.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Sica Media for advertising Serina Therapeutics for a one day marketing program on June 11, 2024.  Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising Serina Therapeutics for a one day marketing program on December 18, 2024.  It might seem obvious, but while our client claims not to own any shares in Serina Therapeutics, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Serina Therapeutics, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.